[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-calcification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-calcification":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,79,111,139,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100420349","use-of-discarded-surgery-human-tissue-specimens-for-basic-science-research-100420349",false,"NCT04753593","Use of Discarded Surgery Human Tissue Specimens for Basic Science Research","HumTisRes","Inclusion Criteria:\n\n* Patients undergoing surgery in the Cardiac Surgery and Orthopedic Surgery departments of the CHU Amiens-Picardie\n* patients who will be beforehand informed\n* patients who will not be opposed to this study.\n\nExclusion Criteria:\n\n* HIV and hepatitis positive patients","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Although it is now established that calcification process result from the joint and coordinated action of different cell types, many areas of shadow remain regarding the spatio-temporal implementation of these events. Highlighting these processes requires additional research to consider new approaches to clinical management of patients with such conditions. It is in this context that the investigators need to use residual human tissue fragments resulting from surgery which are not intended to be used for clinical-biological management of patients. The use of these pseudonymised human tissues will allow the investigators to conduct in vitro cell culture experiences.",[24,25],"Osteoblast","Vascular Calcification",[27,25,28,29,30,31],"osteoblast","vascular smooth muscle cell","Cardiac valve calcification","Valvular interstitial cell","bone tissue","RECRUITING","2026-06-12",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":36},"2021-01-04",{"date":40,"type":20},"2026-06",{"name":42,"class":43},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":44},"100614468","comparison-of-ra-ivl-and-ra-shp-in-calcified-coronary-lesions-100614468","NCT07279987","Comparison of RA-IVL and RA-SHP in Calcified Coronary Lesions","Comparison of Combined Rotational Atherectomy With Intravascular Lithotripsy Versus Super-High Pressure Balloon Angioplasty for Heavily Calcified Coronary Lesions (CRUSH-CALC Study)","CRUSH-CALC","Inclusion Criteria:\n\n* Age ≥18 years, able to understand the study purpose and voluntarily sign written informed consent\n* Coronary angiography confirmed severe calcified lesions (Mintz classification ≥Grade 2), with IVUS unable to pass or showing calcification grade ≥2\n* Native coronary artery lesion\n* Target vessel diameter 2.5-4.0mm\n* Lesion length ≤30mm, suitable for rotational atherectomy\n* Clinical indication for PCI: Ischemic cardiomyopathy confirmed by functional testing (e.g., myocardial nuclear scan); Clinical presentation of stable or unstable angina with clear PCI indication\n* Planned rotational atherectomy as initial calcium modification technique\n* After rotational atherectomy (burr diameter ≤1.5mm), IVUS shows calcification grade still ≥2, or \\\u003C2 but 2.5mm non-compliant balloon cannot achieve adequate expansion at nominal pressure\n* Informed consent signed and agreement to participate in clinical trial\n* Able to comply with treatment and complete follow-up\n\nExclusion Criteria:\n\n* Acute myocardial infarction (AMI) within 7 days, as condition may be unstable and increase periprocedural complication risk\n* Target vessel characteristics: Target vessel with thrombus formation, may increase intraoperative embolism risk; Target vessel with chronic total occlusion (CTO), unable to be treated by rotational atherectomy and calcium modification techniques; Target lesion is in-stent restenosis; Target lesion located in coronary artery bypass graft\n* Severe heart failure: left ventricular ejection fraction \\\u003C30%, poor tolerance to PCI surgery, may increase perioperative mortality risk\n* Previous treatment history: previous stent implantation or rotational atherectomy in the same target vessel, as complex lesion structure or confounding treatment effects may exist\n* Special medical history: Known contrast allergy or severe bleeding tendency (such as active gastrointestinal bleeding), may be unable to tolerate PCI surgery; Patients with other serious comorbidities, expected to be unable to complete 12-month follow-up (such as life expectancy \\\u003C12 months)\n* Pregnancy or lactation: pregnant or lactating women, as intraoperative radiation and drug effects may adversely affect mother and child\n* Participation in other clinical trials: patients simultaneously participating in other interventional clinical trials, to avoid mutual influence of different trial intervention measures",{"count":54,"type":20},162,"INTERVENTIONAL",[57],"NA","Study Design Prospective, multicenter, single-blind, randomized controlled trial\n\nHypothesis In patients with severely calcified coronary lesions undergoing rotational atherectomy (Rota), post-rotational lesion optimization using intravascular lithotripsy (IVL) is non-inferior to super high-pressure balloon (SHPB) in terms of final minimal lumen diameter (MLD), with potential differences in acute lumen gain, stent expansion, and periprocedural complications.\n\nInclusion Criteria\n\n* Age ≥ 18 years\n* De novo coronary lesions with severe calcification confirmed by angiography (moderate-to-severe calcification) and IVUS (calcification grade ≥2 by Mintz classification, or IVUS cannot pass)\n* Target vessel reference diameter 2.5-4.0 mm\n* Lesion length ≤ 30 mm suitable for rotational atherectomy\n* Clinical evidence of ischemia (stable or unstable angina, or functional ischemia testing)\n* Planned rotational atherectomy with residual calcification grade ≥2 post-Rota (burr ≤1.5 mm), or inadequate expansion with 2.5 mm non-compliant balloon at nominal pressure\n* Written informed consent provided\n\nExclusion Criteria\n\n* Acute myocardial infarction within 7 days\n* Presence of thrombus, chronic total occlusion (CTO), or in-stent restenosis in target vessel\n* Lesion located in coronary artery bypass graft\n* Severe heart failure (LVEF \\\u003C 30%)\n* Previous stenting or rotational atherectomy in same target vessel\n* Known contrast allergy, active bleeding, severe comorbidity with life expectancy \\\u003C 12 months\n* Pregnancy or lactation\n* Participation in other interventional clinical trials\n\nRandomization\n\nAfter initial rotational atherectomy (burr ≤1.5 mm), eligible patients meeting imaging-defined \"need for further lesion optimization\" criteria will be randomized 1:1 to:\n\nRota + IVL group: Intravascular lithotripsy using pulsed ultrasonic energy (up to 80 pulses, 8 cycles) followed by stent implantation Rota + SHPB group: Super high-pressure balloon (≥30 atm) expansion followed by stent implantation Stratification by: Study center, Reference vessel diameter (2.5-3.0 mm vs. \\>3.0-4.0 mm)\n\nPrimary Endpoint Post-procedural minimal lumen diameter (MLD) measured by OCT\u002FIVUS immediately after stent implantation and post-dilation Secondary Endpoints Procedural efficacy: Acute lumen gain, final stent expansion rate, minimal stent area, stent apposition Procedural safety: Periprocedural complications including coronary perforation, dissection, no-reflow\u002Fslow flow, acute stent thrombosis Clinical outcomes: MACE (composite of cardiac death, myocardial infarction, target vessel revascularization) at 30 days, 6 months, and 12 months Other outcomes: Major bleeding (BARC ≥2), acute kidney injury (KDIGO criteria), procedure duration, contrast volume, radiation exposure Sample Size Total: 162 patients (81 per group)\n\nIn-hospital monitoring until discharge Clinical follow-up at 30 days, 6 months, and 12 months Imaging follow-up (OCT\u002FIVUS) selectively at designated centers as per protocol or clinical indication\n\nStudy Centers\n\nThree tertiary hospitals with extensive experience in complex coronary interventions and calcified lesion management:\n\n* Beijing Chaoyang Hospital, Capital Medical University (coordinating center)\n* China-Japan Friendship Hospital\n* Xinhua Hospital, Shanghai Jiao Tong University School of Medicine\n\nStudy Duration January 2026 to December 2028 (3 years)",[25],[61,62,63,64,65,66,67,68],"Coronary Artery Disease","Percutaneous Coronary Intervention","Vascular calcification","Rotational atherectomy","Intravascular lithotripsy","Super high-pressure balloon","Major adverse cardiovascular events","Plaque modification","NOT_YET_RECRUITING","2025-12-22",{"date":72,"type":36},"2025-12-29",{"date":74,"type":20},"2026-01-01",{"date":76,"type":20},"2028-12-31",{"name":78,"class":43},"Lin Zhao",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":55,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100605547","analysis-of-the-influence-of-dialysis-fluid-composition-on-vascular-calcification-in-patients-with-chronic-kidney-disease-undergoing-hemodialysis-100605547","NCT07163936","Analysis of the Influence of Dialysis Fluid Composition on Vascular Calcification in Patients With Chronic Kidney Disease Undergoing Hemodialysis","CalCio-HD","Inclusion Criteria:\n\n* Adults (≥18 years old) on maintenance hemodialysis for more than 3 months\n* Clinically stable patients with a well-functioning vascular access\n* Residual urine output ≤ 250 mL\u002Fday\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or intolerance to any component of the dialysates\n* Active malignancy or infectious\u002Finflammatory disease\n* Planned living donor kidney transplant before study completion\n* Current treatment with vitamin K antagonists (coumarins)\n* Severe hypocalcemia or poorly controlled secondary hyperparathyroidism\n* Any condition that, in the investigator's judgment, contraindicates participation or affects study compliance",{"count":87,"type":20},80,[57],"The goal of this clinical trial is to find out if using a citrate-based dialysate with added magnesium during hemodialysis can help slow down or prevent the hardening of blood vessels (vascular calcification) in adults on long-term dialysis.\n\nThe main questions the study will try to answer are:\n\nDoes citrate-based dialysate with magnesium improve the blood's ability to prevent calcium buildup (measured by a test called T50) compared to acetate-based dialysate?\n\nDoes it modify magnesium, calcium and parathyroid hormone (PTH) levels in the blood?\n\nDoes it lower the chances of heart problems or death?\n\nResearchers will compare two groups: one will receive acetate-based dialysate, and the other will receive citrate-based dialysate with magnesium.\n\nParticipants will:\n\nReceive one of the two types of dialysate during their regular hemodialysis sessions for 12 months\n\nHave regular blood tests\n\nBe monitored for any heart problems and for overall health during the study",[25,91,92],"Hemodialysis","Cardiovascular Disease (CKD)",[94,95,96,97,98,99,100,101],"hemodialysis","dialysate","citrate dialysate","acetate dialysate","magnesium supplementation","calcification propensity","vascular calcification","dialysate composition","2025-09-01",{"date":104,"type":36},"2025-09-09",{"date":106,"type":20},"2025-09-03",{"date":108,"type":20},"2026-09-06",{"name":110,"class":43},"Hospital Clinic of Barcelona",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":55,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":44},"100571612","phase-4-guide-cac-statin-ezetimibe-without-aspirin-vs-statin-monotherapy-with-aspirin-in-high-coronary-calcification-100571612","NCT06722521","GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","Comparison of Intensive Lipid-Lowering Therapy With a Statin-Ezetimibe Combination (Without Aspirin) vs. Statin Monotherapy (With Aspirin) In Asymptomatic Patient With Coronary Artery Calcification","Inclusion Criteria\n\n1. Adults aged 19 years and older\n2. Asymptomatic patients with significant coronary calcification (Agatston score ≥ 100) and no physiologically significant coronary artery disease (CAD)\n\n   * The coronary CT scan used to establish the CAC score must be performed within 3 years prior to randomization.\n   * The assessment of physiological significance must be performed within 6 months prior to randomization\n3. Participants will be eligible for inclusion regardless of prior statin or anti-platelet agents use.\n\nExclusion Criteria\n\n1. Major ASCVD events (clinically documented ASCVD)\n\n   If at least one of the following criteria is present via patient history, physical examination, or medical records at the time of screening, the patient is not eligible:\n   * Acute coronary syndrome (MI or unstable angina)\n   * Coronary revascularization (PCI, CABG) or other arterial revascularization\n   * Ischemic stroke (Not TIA)\n   * Symptomatic peripheral arterial disease (history of claudication with ABI \\\u003C0.90, or previous revascularization or amputation\n2. Patients with physiologically significant CAD\n\n   * Moderate to severe CAD (diameter stenosis \\>50%) on CCTA with positive strest test (thallium, treadmil, stress echocardiography)\n   * Moderate to severe CAD (diameter stenosis \\>50%) on CAG with positive fractional flow reserve (FFR) \\\u003C 0.8\n3. Patients with familial hypercholesterolemia.\n4. Patients with low-density lipoproteins cholesterol (LDL-C) ≥ 190 mg\u002FdL regardless taking a statin or not.\n5. Continuation of PCSK9 inhibitor is required during the clinical trial\n6. Patients with chronic kidney disease (\\\u003CeGFR 30mL\u002Fmin\u002F1.73m2)\n7. Advanced liver disease (Child-Pugh B or C)\n8. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \\> 5 times upper limit of normal).\n9. History of gastrointestinal bleeding, peptic ulcer, or intracranial hemorrhage within 6 months prior screening\n10. Patients with a history of organ transplantation who are on immunosuppressive therapy\n11. Concurrent use of other medications that may increase bleeding risk such NOAC and warfarin\n12. A history of significant allergic reaction to aspirin or statin\u002Fezetimibe\n13. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.\n14. Life expectancy \\\u003C 1 years for any non-cardiac or cardiac causes.\n15. Patient's pregnant or breast-feeding or child-bearing potential.\n16. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.\n17. Unwillingness or inability to comply with the procedures described in this protocol","19 Years",{"count":120,"type":20},7435,[122],"PHASE4","A Multicenter, randomized trial comparing the efficacy and safety of intensive lipid-lowering therapy using a statin-ezetimibe combination without aspirin versus statin monotherapy with aspirin in asymptomatic patients with coronary artery calcification",[125,25],"Primary Prevention",[127,128,129],"Cardiovascular Diseases","Aspirin","Statin","2025-08-04",{"date":132,"type":36},"2025-08-07",{"date":134,"type":36},"2025-07-09",{"date":136,"type":20},"2032-10-31",{"name":138,"class":43},"Asan Medical Center",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":55,"phases":148,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100585540","phase-1-pentoxifylline-for-vascular-calcification-in-kidney-disease-100585540","NCT06903689","Pentoxifylline for Vascular Calcification in Kidney Disease","Exploring the Potential Effect of Pentoxifylline in Mitigating Vascular Calcification in Chronic Kidney Disease Patients","PTX-CALC-CKD","Inclusion Criteria:\n\n* Estimated Glomerular Filtration Rate (eGFR) less than 60 ml\u002Fmin\u002F1.73 m² and greater than or equal to 15 ml\u002Fmin\u002F1.73 m².\n* Adult patients, age 18 years or older.\n* Diagnosis of Chronic Kidney Disease (CKD).\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients currently undergoing regular hemodialysis.\n* History of kidney transplantation or are kidney transplant recipients.\n* Pregnant females.\n* Patients with a history of coronary artery bypass grafting (CABG).\n* Known allergy or contraindication to pentoxifylline.\n* Inability to comply with study procedures or attend follow-up visits.",{"count":87,"type":20},[149,150],"PHASE1","PHASE2","This study is research to find out if the drug pentoxifylline can help prevent or lessen the problem of blood vessel hardening (vascular calcification) in people with chronic kidney disease (CKD). People with CKD are at higher risk for heart problems and blood vessel hardening. Vascular calcification happens when calcium builds up in the blood vessels, making them stiff. Pentoxifylline is a drug that might have helpful effects that could reduce this hardening. In this study, some CKD patients will receive pentoxifylline in addition to their usual medications, while others will only receive their usual medications. The researchers will then compare the amount of vascular calcification in both groups over 6 months to see if pentoxifylline makes a difference. The goal is to learn if pentoxifylline could be a new way to protect the blood vessels of people with chronic kidney disease.",[153,25,154],"Chronic Kidney Disease","Kidney Failure, Chronic",[154,25,156,157],"Pentoxifylline","CKD","2025-03-25",{"date":160,"type":36},"2025-04-01",{"date":162,"type":20},"2025-04-15",{"date":164,"type":20},"2025-10-30",{"name":166,"class":43},"Mansoura University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":44},"100430743","coronary-artery-calcification-in-type-2-diabetes-mellitus-uscac-study-100430743","NCT04889053","Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)","Prospective Cohort Study of Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Type 2 diabetes is diagnosed according to WHO diagnostic criteria\n* Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation\n* Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily\n\nExclusion Criteria:\n\n* Those have received coronary artery stenting or coronary artery bypass grafting\n* Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\\[GFR \\\u003C 45ml\u002F(min.1.73m2) or dialysis patients\n* Malignant tumor\n* Mental illness or mental retardation\n* Pregnant or lactating women or those with fertility planning\n* Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification\n* Contraindications of contrast agents\n* Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements",{"count":175,"type":20},1400,"Coronary artery calcification (CAC) is a common complication of type 2 diabetes mellitus(T2DM), which can significantly increase all-cause mortality and the incidence of serious cardiovascular events, and increase the burden of the national economy. The epidemiological characteristics and the clinical progress of CAC are still not clear. Moreover, the pathogenesis of CAC has not yet been fully elucidated, and lack of specific diagnostic indicators. Arterial calcification is an active, reversible, and multifactorial biological process like bone formation. It is generally believed that early detection of calcification lesions and active targeted treatment may be the key to prevention and treatment of vascular calcification. In addition, statins are commonly used in patients with dyslipidemia and can stabilize CAC plaque. However, the timing, dosage and effect of statins are controversial. Moreover, our previous study found that the expression of miR-32 is significantly elevated in patients with CAC, and can promoting vascular calcification. Herein, this study is to conduct a prospective cohort study on T2DM patients with CAC in Hunan province through a multidisciplinary and multi-center cooperation model, the main research objectives include the following three parts: ① To identify the prevalence, incidence, and characteristics of CAC in T2DM patients in Hunan province, and to build a risk assessment model. ② To observe the effects of statins on the occurrence and development of CAC in patients with T2DM, and to provide clinical data for the improvement of medication guidelines; ③To observe the dynamic changes of serum miR-32 in the progression of CAC in patients with T2DM, and to explore its possibility as a serological diagnosis or prognostic bio-maker of CAC. The completion of this research project is expected to bring a new breakthrough in the field of early diagnosis, prognosis evaluation, and intervention treatment of patients with T2DM combined with CAC, and provide an important reference for the formulation of cardiovascular disease prevention and control strategy.",[178,25,179,180,181,182],"Type 2 Diabetes","Coronary Artery Calcification","Strains","Epidemiology","microRNA",[178,63,181,184],"microRNA-32","2021-09-27",{"date":187,"type":36},"2021-09-29",{"date":189,"type":36},"2021-06-01",{"date":191,"type":20},"2030-12-31",{"name":193,"class":43},"University of South China"]